Bicocca Open Archive

Logo unimib boa
BIDOLI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.951
EU - Europa 2.661
AS - Asia 1.395
AF - Africa 9
SA - Sud America 5
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.026
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.852
IE - Irlanda 607
IT - Italia 491
SG - Singapore 457
CN - Cina 456
SE - Svezia 400
RU - Federazione Russa 396
DE - Germania 371
HK - Hong Kong 301
GB - Regno Unito 117
CA - Canada 95
UA - Ucraina 91
IN - India 54
FI - Finlandia 46
VN - Vietnam 42
DK - Danimarca 37
AT - Austria 36
TR - Turchia 27
FR - Francia 20
BE - Belgio 19
ID - Indonesia 18
JP - Giappone 14
IR - Iran 8
KR - Corea 8
NL - Olanda 8
PL - Polonia 7
BR - Brasile 4
ES - Italia 4
MU - Mauritius 4
RO - Romania 3
AM - Armenia 2
AU - Australia 2
BD - Bangladesh 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
EG - Egitto 2
EU - Europa 2
MX - Messico 2
SA - Arabia Saudita 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
CL - Cile 1
ET - Etiopia 1
GR - Grecia 1
LV - Lettonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
PR - Porto Rico 1
SC - Seychelles 1
SI - Slovenia 1
Totale 11.026
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.331
Fairfield 850
Dublin 599
Ashburn 556
Woodbridge 481
Wilmington 430
Seattle 383
Chandler 372
Singapore 369
Cambridge 320
Houston 318
Hong Kong 289
Frankfurt am Main 264
Princeton 248
New York 245
Jacksonville 163
Altamura 122
Lawrence 118
Shanghai 114
Beijing 99
Milan 87
Santa Clara 73
San Diego 70
Dearborn 63
Toronto 46
Andover 44
Boardman 34
Vienna 34
Nanjing 32
Helsinki 30
London 30
Guangzhou 28
Hangzhou 26
Ottawa 25
Turin 25
Dallas 23
Falls Church 23
Dong Ket 22
Pune 22
Washington 22
Brussels 18
Jakarta 18
Norwalk 18
Tianjin 14
Hebei 13
Jinan 13
Redmond 13
Rome 13
Lachine 12
Torre Del Greco 12
Munich 11
Tappahannock 10
Zhengzhou 10
Los Angeles 9
Chicago 8
Perugia 8
Phoenix 8
Edmonton 7
Fremont 7
Genoa 7
Lissone 7
Nanchang 7
Kilburn 6
Kowloon 6
Mountain View 6
Shenyang 6
Torino 6
Carignano 5
Lodz 5
Mumbai 5
Ningbo 5
Prescot 5
San Mateo 5
Bari 4
Desio 4
Hefei 4
Jiaxing 4
Kunming 4
Laurel 4
New Bedfont 4
Tokyo 4
Wuhan 4
Bergamo 3
Bologna 3
Bonndorf 3
Broni 3
Camogli 3
Changchun 3
Changsha 3
Hanoi 3
Huizen 3
Kocaeli 3
Lappeenranta 3
Montréal 3
Sacramento 3
Seoul 3
Seregno 3
Suwon 3
Aci Catena 2
Acton 2
Totale 8.821
Salva come PNG Salva come JPEG
Nome #
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 296
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 253
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 249
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 237
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 233
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 228
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 218
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 216
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab 211
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 193
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 183
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 183
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 176
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 175
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 166
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 161
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 156
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 154
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 145
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 142
When progressive dysphagia could be related to an “old friend” – a case report 136
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial 135
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin‐2 in advanced small cell lung cancer patients 133
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 126
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis 125
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 123
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 123
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 121
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 111
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 111
Novel cytotoxic chemotherapies in small cell lung carcinoma 107
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors 102
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 101
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 99
Drugs ten years later: epirubicin 93
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer 93
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 93
Malignant mesothelioma in subjects with Marfan's syndrome and Ehlers-Danlos syndrome: only an apparent association? 92
Esophageal squamous cell carcinoma: MRI evaluation of mediastinum 90
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial 90
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 89
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 88
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 87
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma 87
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 85
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial 84
Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial 83
Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis 82
Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival 82
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 82
Focus on nivolumab in NSCLC 81
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 80
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 79
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: Attempts to improve long-term outcome 78
Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC) 78
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 78
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial 77
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 76
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer 76
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 74
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? 74
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 74
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 74
Oxaliplatin doublets in non-small cell lung cancer: A literature review 73
Prognosis after nonradical resections for small cell lung carcinoma (SCLC) 73
Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy 72
Pilot study with adriamycin and ifosfamide in small cell lung cancer 72
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 71
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 71
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial 70
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 70
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study 69
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 66
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer 66
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 65
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial 65
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) 65
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus 65
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 65
EAGLES study: First-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer 64
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial 63
Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents 63
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study 62
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 62
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study 61
Esophageal carcinoma: radiochemotherapy 61
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC) 61
Combined radiation and chemotherapy in esophageal cancer 61
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer 60
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients 60
Radiologic examination in assessing the response to chemoradiotherapy of esophageal spinocellular carcinoma 59
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial 58
Isolated cardiac metastasis from squamous cell esophageal cancer 58
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial 58
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 57
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma 57
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset 56
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial 55
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial 55
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer 55
Totale 10.371
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.502
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.502
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.953 0 0 0 0 62 101 135 681 406 252 236 80
2020/20212.579 132 136 324 240 137 185 293 324 219 220 179 190
2021/20221.233 107 156 159 71 40 86 79 62 67 53 96 257
2022/20231.894 273 635 127 134 83 303 33 99 131 21 30 25
2023/20241.867 32 36 59 59 272 498 377 101 205 14 17 197
2024/20251.102 219 500 198 171 14 0 0 0 0 0 0 0
Totale 11.634